Canada’s pharmaceutical and CDMO/CMO sector is evolving rapidly. However, growth brings complex operational and financial challenges. Ayming helps organizations navigate uncertainty and unlock funding to drive drug development, scale manufacturing, and achieve sustainable growth.
Pharmaceutical & CDMO/CMO
Addressing the key challenges
Canada’s pharmaceutical sector faces a unique mix of financial, regulatory, and R&D-related challenges, shaped by global competition, and evolving regulations.
Overcoming these challenges will demand close collaboration between industry, government, and healthcare providers. Within this ecosystem, contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) support drug sponsors by providing outsourced services.
Key innovation areas come with unique hurdles:
-
Biologics & Advanced Therapies: Ensuring batch consistency and long-term therapeutic durability
-
Continuous Manufacturing: Driving real-time process control and efficient scale-up
-
Rising Drug Development Costs: Managing the high expense of bringing new therapies to market
-
Patent Cliffs – Mitigating revenue loss from loss of exclusivity and generic competition
-
Data Integrity & Reproducibility: Safeguarding reliable clinical and manufacturing data across global sites
-
Scaling Up Production: Overcoming challenges to achieve commercial-scale manufacturing
These challenges require major investment that could be supported by comprehensive range of funding opportunities, government grants, loans, tax incentives, and innovation programs. Whether you are sponsoring clinical trials, developing or scaling up processes, acquiring equipment, increasing your manufacturing capabilities, protecting your intellectual properties (IP) or investing in people, tailored funding options are available to fuel your growth.
Navigating multiple funding sources and aligning technical projects with finance teams can be complex. At Ayming, we simplify this process by helping you access the right combination of funding and tax incentives. Partner with us to maximize your capital, reduce administrative burdens, and accelerate your growth.
How we can help maximize your results
We help you identify and capture all eligible activities embedded in your different projects. From clinical trails, development or scale up of processes and continuous manufacturing advancements.
Our full-service support includes:
- Framing SR&ED-eligible activities: Canadian pharmaceutical & CDMO/CMO companies must maintain strict GMP compliance, which can limit flexibility in experimentation or force slower iteration cycles. R&D often overlaps with quality and production, making it harder to isolate and document SR&ED-eligible activities. We work with your technical teams to extract and frame the eligible portions of your work. This may be embedded in regulatory compliance, protocol design, assay development or continuous manufacturing trails. Ayming also trains and coaches your teams to spot eligible activities in real time
- Technical Expertise and Project Framing: Our seasoned consultants will bridge the communication gap between the technical teams and CRA auditors, framing complex innovation in compliant language. We will translate R&D into CRA’s three-part test: technological uncertainty, experimentation, and advancement. We will help differentiate eligible experimental work from routine engineering or production.
- Clarifying eligibility when work is client-funded: Many CDMO/CMO assume their activities are not eligible because they are done for clients. In reality, these service providers can often claim SR&ED if they retain risk and perform eligible R&D in Canada. This includes opportunities even when working with foreign sponsors. We help assess contract structures, intellectual property rights, and technical scope to determine what qualifies and how to structure future engagements for eligibility.
- Accurate cost tracking across contracts: We help you identify and separate eligible SR&ED costs from non-eligible commercial activities, including how to allocate staff time, subcontractor fees, and consumables used in eligible work. We also advise you on how to structure internal time tracking to clearly reflect SR&ED activities within client-driven projects.
- Audit defense and compliance strategy: The SR&ED program is highly technical and continually evolving. Ayming provides early warnings on audit trends and policy shifts that affect pharmaceutical and CDMO/CMO sector, and if you are selected for review, we manage the end-to-end audit response to minimize disruption to your business.
Whether you are optimizing drug formulations, conducting clinical trails, developing or scaling continuous manufacturing, we transform your efforts into high-impact funding claims that maximize financial returns and ensure compliance.
We guide pharmaceutical and CDMO/CMO companies through the full spectrum of direct funding. From government grants and repayable loans to strategic programs that accelerate innovation and manufacturing capacity.
Our mission is to secure the capital you need to fuel pharmaceutical growth, advance clinical research, and scale biomanufacturing. We work closely with your leadership to align projects with federal and provincial priorities such as biomanufacturing expansion, drug development, and scaling of your production lines. Our team builds compelling applications that maximize funding success while positioning your company at the forefront of Canada’s health innovation strategy.
Our comprehensive support includes:
-
Grant Applications
-
Pre-Application Strategy & Positioning
-
Government Relationships & Advocacy
-
Funding Landscape Mapping & Strategy
-
Foreign Direct Investment (FDI) Funding Strategy
-
Post-Approval Compliance & Claim Support
Whether you’re pioneering novel drug production protocols, applying AI to accelerate production and scale manufacturing, or establishing new production lines to strengthen Canada’s health resilience, we help you build a strategic funding roadmap that fuels your projects and drives sustainable growth.
More about Government Grants, Loans & Innovation Funding
We deliver a tailored funding strategy that aligns tax incentives, government grants, and loans across your product lifecycle, maximizing total recoverable funding while minimizing administrative complexity.
Our consulting services include:
- Integrated Funding Strategies: Ayming will work with the finance team to develop holistic funding strategies that combine SR&ED tax credits, government grants, and repayable loans designed specifically for pharmaceutical & CDMO/CMO companies. We will ensure to avoid double dipping or non-compliance across programs.
- Stage-Based Alignment: Aligning funding sources to your milestones, from clinical trials to drug production development and full-scale manufacturing.
- Risk Reduction & Cash Flow Optimization: Layering incentives to reduce upfront capital risk, enhance cash flow, and extend your project runway.
- Policy-Informed Positioning: Ensuring alignment with evolving healthcare priorities such as personalized medicine, AI integration, and biomanufacturing excellence to boost competitiveness and funding approvals.
With deep expertise in pharmaceutical innovation and government funding, Ayming is your trusted partner in turning complex R&D challenges into financial opportunities, accelerating your path from discovery to market impact.
More about Strategic Funding Alignment & Consulting
SR&ED Tax Credit | Direct Funding
Ayming guides the pharmaceutical and CDMO/CMO sector to decrease cost of strategic investments in equipment, facilities, and production processes by maximizing the impact of manufacturing tax credits. Companies in this sector can often benefit from multiple tax credits alongside grants, creating a layered funding strategy that reduces capital costs, strengthens cash flow, and accelerates scale-up.
Our experts ensure these programs are fully optimized and compliant, empowering pharmaceutical manufacturers and CDMOs/CMOs to expand production capacity, adopt advanced technologies, and achieve sustainable growth.
More about Manufacturing Tax Credit
OMMITC | MITC | MPITC | C3i
We support pharmaceutical manufacturers and CDMOs/CMOs in leveraging Quebec’s Incentive Deduction for the Commercialization of Innovations (IDCI), a tax incentive that reduces the provincial tax rate on eligible income from qualified intellectual property assets (QIPAs) from 11.5% to as low as 2%. This incentive applies to corporations that conduct R&D activities in Quebec and earn income from the commercialization of QIPAs, either in Quebec or elsewhere. By integrating this incentive with strategic investments in equipment, facilities, and production processes, companies can enhance the financial efficiency of their operations, accelerate commercialization, and maximize the return on their intellectual property.
Our experts ensure these programs are fully optimized and compliant, empowering pharmaceutical manufacturers and CDMOs/CMOs to scale innovative solutions and strengthen their competitive advantage.
Ayming helps pharmaceutical manufacturers and CDMOs/CMOs identify and recover overpaid sales and property taxes, turning overlooked expenses into valuable funding opportunities. By analyzing historical and current transactions, our experts uncover eligible claims, ensure full compliance, and implement efficient recovery processes. This approach allows companies to reinvest recovered funds into equipment, facilities, and advanced manufacturing initiatives, enhancing operational efficiency and supporting strategic growth across the pharmaceutical sector.
Find out how much your company could recover by contacting us today.
More about Sales Tax Recovery
Advancing Innovation in Pharma & CDMO/CMO
Explore our latest insights addressing the unique challenges and funding opportunities driving breakthroughs in pharmaceutical development and clinical research.
